3D-Bioprinting holds much promise in advancing medicine as tool to replicate cellular complexity of tissue environment ex vivo for drug screening and as a means of engineering well-defined functional tissue units for transplantation.Continue reading “What is the current 3D Bioprinting landscape?”
BioInks the Lynchpin of 3D Bioprinting: Challenges and Opportunities – Presented by Prasad Shastri, University of Freiburg, at the 3D Medical Conference, which takes place on January 30-31, 2019, at MECC Maastricht, The Netherlands.
Success begets success. This adage is highly relevant for the field of 3D bioprinting today. While the 3D bioprinting as a field has seen explosive growth in the past 5 years, with impressive developments in hardware, the absence of notable translational successes is a clear area of concern. Just as the development of affordable inks drove the adoption of color printers in every household, bioinks are expected to be the lynchpin of 3D bioprinting.
Currently, the bioink segment is largely dominated by methacrylated gelatin (GelMa), alginate and combinations thereof. While these biomaterials are adequate for bioprinting in the laboratory, their translational potential is limited. Continue reading “BioInks the Lynchpin of 3D Bioprinting: Challenges and Opportunities – Presented by Prasad Shastri, University of Freiburg”